Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 104 clinical trials
Treatment of Intermittent Claudication by G-CSF-mobilized PB-MNC

This study will investigate the efficacy of G-CSF mobilized mononuclear cell injection of patients with PAD who presented with intermittent claudication. Forty PAD patients who presented with

arterial occlusive disease
intermittent claudication
g-csf
  • 46 views
  • 14 Feb, 2022
  • 1 location
A Randomized Phase II Trial Comparing Stem Cell Mobilization With Chemotherapy and Cytokine (G-CSF) Versus Cytokine (G-CSF) Alone in Myeloma Patients (MOCCCA-trial). (MOCCCA)

This study aims to demonstrate that the mobilization with cytokine stimulation with G-CSF alone is non-inferior as compared to the standard mobilization with chemotherapy and G-CSF while

granulocyte colony stimulating factor
filgrastim
melphalan
chemotherapy regimen
colony stimulating factor
  • 4 views
  • 22 Oct, 2022
  • 1 location
Treatment of No-option CLI by G-CSF-mobilized PB-MNC

This study will investigate the efficacy of G-CSF mobilized mononuclear cell injection of patients with PAD who presented with no-option CLI. Forty no-option CLI patients who presented with rest

rest pain
granulocyte colony stimulating factor
gangrene
ischemic ulcer
  • 3 views
  • 14 Feb, 2022
  • 1 location
G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

potential patients can benefit from immunotherapy is an urgent problem to be solved at present. Studies have shown that G-CSF can significantly increase the proportion of effector cells dominated by

  • 0 views
  • 24 Mar, 2022
  • 1 location
PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

is about 25%. Recent studies have shown that G-CSF can significantly increase the proportion of effector cells dominated by CD4+ T cells, improve the diversity of peripheral blood TCR, and

  • 0 views
  • 22 Mar, 2022
  • 1 location
Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma

compare with filgrastim. This study is to evaluate efficacy and safety in chemotherapy-induced neutropenia of once-per-cycle Mecapegfilgrastim Injection(PEG-G-CSF) and daily G-CSF in Patients with

lymphoma
chemotherapy regimen
granulocyte colony stimulating factor
filgrastim
  • 0 views
  • 04 Oct, 2022
  • 1 location
High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma

This study was a multi-center, randomized, prospective study. The purpose is to clarify that high-dose VP-16+G-CSF has better mobilization efficiency and less toxic and side effects compared

etoposide
granulocyte colony stimulating factor
filgrastim
white blood cells
chemotherapy regimen
  • 0 views
  • 07 Oct, 2022
  • 1 location
  • 0 views
  • 27 Oct, 2022
  • 1 location
Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM (DCM-Support)

The DCM SUPPORT study is a single centre, single arm study evaluating the change in left ventricular ejection fraction with the combines use of bone marrow derived stem cells and G-CSF with a

ejection fraction
dilated cardiomyopathy
medical therapy
ct scan
heart failure
  • 1 views
  • 14 Apr, 2022
  • 1 location
A Study Comparing the Effects on Melanoma With High Dose IFN Alone vs Cisplatin Velban DTIC IL2 IFN and G CSF

What is the overall survival and disease-free survival between patients with high risk melanoma who recieve high dose interferon Alphe 2b versus Cisplatin, Vinblastine, DTIC plus IL-2 and Interferon. Also what toxicities of these two regimens in the patient population.

dacarbazine
vinblastine
filgrastim
interferon
  • 12 views
  • 07 Nov, 2020
  • 1 location